Pavadi Capital’s Maravai LifeSciences MRVI Stock Holding History

Pavadi Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-144,569	Closed	-$3.69M	–	24
2022 Q3	$3.69M	Sell	144,569 -13,951	-9%	-$350K	3.53%	18
2022 Q2	$4.5M	Buy	158,520 +25,241	+19%	+$800K	4.08%	13
2022 Q1	$4.7M	Sell	133,279 -12,331	-8%	-$413K	4.14%	11
2021 Q4	$6.1M	Buy	+145,610	New	+$5.9M	4.63%	10

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Pavadi Capital's MRVI Position: Q4 2022 in Review

Pavadi Capital sold out of Maravai LifeSciences (MRVI) in Q4 2022, closing a stake of 144,569 shares — an estimated $3.69M sold.

Pavadi Capital first reported a position in MRVI in Q4 2021 and held it in 4 quarters. The position peaked at $6.1M in Q4 2021. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

Pavadi Capital reported no remaining Maravai LifeSciences position as of Q4 2022 after selling out during the quarter.
Pavadi Capital sold 144,569 Maravai LifeSciences shares in Q4 2022, an estimated $3.69M.
Pavadi Capital first reported a position in Maravai LifeSciences in Q4 2021 and held it in 4 quarters.
Pavadi Capital's Maravai LifeSciences position peaked at $6.1M in Q4 2021.
212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on Pavadi Capital's 13F filing for Q4 2022, filed 14 Feb 2023.